Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual sublingual immunotherapy with Artemisia annua pollen and house dust mite allergens in allergic rhinitis
ChiCTR2300072517Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Shanxi Medical University
- Start
- Jun 2023
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of artemisia annua allergen extract and Der f in allergic rhinitis (AR) and allergic conjunctivitis (AC) (2 arms), sponsored by First Affiliated Hospital of Shanxi Medical University. Primary endpoints: Total nasal symptoms score and Total medication score. Started Jun 2023; status: recruiting.
02
Drugs
artemisia annua allergen extractDer f
03
Conditions
allergic rhinitis (AR)allergic conjunctivitis (AC)
Beyond the preview
Go deeper on ChiCTR2300072517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072517.